WHX Labs today placed genomic medicine firmly in the spotlight. During the session titled “Molecular diagnostics in the next decade: regional and global perspectives,” experts explored how emerging technologies are reshaping molecular diagnostics. The discussion formed part of the event’s Molecular Diagnostics and Genomics track at Dubai World Trade Centre.
Moreover, the session highlighted both the remarkable progress and the persistent gaps that continue to define the field. WHX Labs runs until tomorrow.
Experts Examine Advances and Persistent Diagnostic Gaps
A distinguished panel of regional and international specialists led the discussion. The panel featured:
- Dr Hemad Yasaei, Head of Molecular Diagnostics & Genomics, National Reference Laboratory
- Dr Ahmed Alfares, Deputy Executive Director, Genomic Medicine Centre of Excellence, King Faisal Specialist Hospital and Research Centre
- Dr Rami Mahfouz, Professor & Head of Division of Clinical Pathology, American University of Beirut Medical Centre
- Dr Ahmad Abu Tayoun, Director, Dubai Health Genomic Medicine Centre
Together, they addressed a critical issue: despite the widespread adoption of whole genome sequencing, many patients still do not receive definitive diagnoses.
Panellists emphasized that closing this diagnostic gap requires more than technological advancement. It demands deeper biological insight and broader integration of multi-omics approaches.
Emerging Technologies Drive the Next Phase of Genomic Testing
Dr Alfares explained that even the best standard-of-care testing leaves approximately 50% of cases unresolved. However, he pointed to promising solutions.
Emerging technologies such as long-read sequencing, multi-omics platforms, and artificial intelligence are advancing the field toward near-complete genomic assemblies and improved functional interpretation.
He stressed that the real opportunity lies not only in identifying genetic variants but also in understanding their biological significance and clinical impact.
In addition, panellists underscored the growing importance of locally derived genomic databases. These resources improve variant interpretation while helping address global knowledge gaps.
From Innovation to Clinical Integration
The discussion then shifted toward clinical adoption. Speakers challenged outdated perceptions around cost, turnaround time, and diagnostic uncertainty.
Thanks to rapid sequencing technologies and declining testing costs, healthcare providers can now integrate genomics into routine clinical practice more efficiently.
As per The Press Release, experts agreed that sustainable implementation depends on balancing innovation with evidence-based application.
Liquid Biopsy and Data Sharing: Complementary Approaches
Looking ahead, panellists examined the evolving role of liquid biopsy. Dr Mahfouz explained that while liquid biopsy is transforming diagnostic capabilities, clinicians should currently use it to complement—not replace—traditional tissue testing.
He added that combining both approaches from the outset enhances sensitivity and strengthens clinical decision-making.
Furthermore, the panel reinforced the need for responsible data sharing frameworks to maximize the benefits of genomic research while maintaining patient privacy and regulatory compliance.
A Comprehensive Platform for Laboratory Innovation
Held under the theme “Molecular Innovations: Transforming laboratory medicine and patient outcomes,” the Molecular Diagnostics and Genomics track features expert-led sessions on:
- Next-generation sequencing implementation
- Rapid molecular testing for infectious diseases
- Advances in oncology biomarkers
- Quality assurance frameworks
- CRISPR diagnostics and AI integration
The program specifically targets molecular technologists, laboratory directors, and pathologists. It addresses real-world challenges in assay validation, bioinformatics workflows, regulatory compliance, and complex molecular data interpretation.
As a result, attendees gain actionable insights to enhance laboratory performance and improve diagnostic accuracy.
Celebrating 25 Years of Laboratory Excellence
The 25th Annual Laboratory Management and Medicine Congress marks a major milestone for WHX Labs. The congress includes nine CME-accredited scientific conference tracks, such as Laboratory Management, Haematology, Clinical Chemistry, Clinical Microbiology, Molecular Diagnostics, Histopathology, Lab Quality Management, and Blood Transfusion Medicine & Cell Therapy.
More than 250 global thought leaders and laboratory specialists are leading the sessions. Together, they reflect on WHX Labs’ 25-year journey in Dubai under the theme: “Celebrating the past and empowering the future of lab quality through innovation and global benchmarking.”
Rejoy Penacerrada, Conference Director at Informa Markets, emphasized that genomic medicine is advancing rapidly. However, he noted that stakeholders must focus on translating innovation into measurable patient impact. He added that discussions like these bridge the gap between technological promise and clinical reality.